NeoGenomics (NEO) Competitors

NeoGenomics (NASDAQ:NEO) and MultiPlan (NYSE:MPLN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, community ranking, earnings, valuation and analyst recommendations.

Is NEO or MPLN more profitable?

NeoGenomics has a net margin of -12.50% compared to MultiPlan's net margin of -122.73%. NeoGenomics' return on equity of -2.72% beat MultiPlan's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeoGenomics	-12.50%	-2.72%	-1.53%
MultiPlan	-122.73%	-8.90%	-1.78%

Do insiders & institutionals believe in NEO or MPLN?

98.5% of NeoGenomics shares are held by institutional investors. Comparatively, 87.2% of MultiPlan shares are held by institutional investors. 1.3% of NeoGenomics shares are held by company insiders. Comparatively, 8.0% of MultiPlan shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Do analysts prefer NEO or MPLN?

NeoGenomics currently has a consensus target price of $19.89, suggesting a potential upside of 42.06%. MultiPlan has a consensus target price of $25.00, suggesting a potential upside of 172.93%. Given MultiPlan's higher possible upside, analysts clearly believe MultiPlan is more favorable than NeoGenomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeoGenomics	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90
MultiPlan	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Does the media favor NEO or MPLN?

In the previous week, MultiPlan had 2 more articles in the media than NeoGenomics. MarketBeat recorded 3 mentions for MultiPlan and 1 mentions for NeoGenomics. MultiPlan's average media sentiment score of 0.39 beat NeoGenomics' score of 0.14 indicating that MultiPlan is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeoGenomics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MultiPlan	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community believe in NEO or MPLN?

NeoGenomics received 491 more outperform votes than MultiPlan when rated by MarketBeat users. Likewise, 70.86% of users gave NeoGenomics an outperform vote while only 37.04% of users gave MultiPlan an outperform vote.

Company	Underperform	Outperform
NeoGenomics	Outperform Votes 501 70.86%	Underperform Votes 206 29.14%
MultiPlan	Outperform Votes 10 37.04%	Underperform Votes 17 62.96%

Which has preferable earnings & valuation, NEO or MPLN?

NeoGenomics has higher earnings, but lower revenue than MultiPlan. NeoGenomics is trading at a lower price-to-earnings ratio than MultiPlan, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeoGenomics	$591.64M	3.03	-$87.97M	-$0.62	-22.58
MultiPlan	$961.52M	0.15	-$91.70M	-$72.40	-0.13

Which has more volatility and risk, NEO or MPLN?

NeoGenomics has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Comparatively, MultiPlan has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500.

Summary

NeoGenomics beats MultiPlan on 12 of the 18 factors compared between the two stocks.